Anthropic (ANTHROPIC) on Solana

Anthropic launched Claude Opus 5.5 on September 22, just ten days after CEO Dario Amodei publicly called for an industrywide slowdown on frontier AI development. The new model performs on par with Anthropic's flagship Claude Fable 5.1 while costing roughly 40% less to run than its predecessor, Opus 5 — with list prices dropping to $4 per million input tokens and $20 per million output tokens. Sonnet 5.5 and Haiku 5.5 are expected to follow in the coming weeks.

The timing underscores a distinction Anthropic appears to be drawing between frontier capability pushes and efficiency-focused releases: Opus 5.5 is an incremental improvement rather than a new capability frontier, allowing the company to advance its commercial position while nominally adhering to the slowdown call's spirit. The release landed within hours of OpenAI cutting its own API prices by 50% with GPT-6 Sol and Luna, intensifying a price war for cost-conscious enterprise customers. For Anthropic, which is reportedly valued above $2 trillion ahead of an anticipated IPO, competing on price while maintaining safety positioning could widen its addressable market among businesses that have been hesitant to commit to premium-tier pricing.

Anthropic has named Accenture as its first embedded safety evaluator, the inaugural concrete step toward implementing CEO Dario Amodei's proposal to slow AI development and subject frontier labs to external accountability. Staff from Faculty, Accenture's specialist AI division acquired in January, will work inside Anthropic with employee-level access to red-team models, conduct alignment assessments, and test safeguards — roles for which no industry standards yet exist. The two companies have jointly committed to invest at least $1 billion over five years to build capacity in the area, with Anthropic funding Faculty's work directly given the "importance and urgency."

The selection of a major management consultancy surprised AI watchers and moved markets: Accenture shares surged roughly 8% after-hours. Anthropic said it chose Accenture for its practical experience deploying AI for large corporations and governments and its functional independence from the AI ecosystem, and stressed that external evaluators "do not reduce our accountability, but help to make it more verifiable." The partnership is non-exclusive; Anthropic said it is in active discussions with research nonprofit METR and other third parties to expand the embedded-evaluator program.

Anthropic has quietly established a physical "wet lab" in the San Francisco Bay Area to complement its AI-directed drug discovery program, according to Reuters. The company's head of life sciences, Eric Kauderer-Abrams, confirmed the operation, noting that biology ultimately requires hands-on experimental validation beyond what models alone can provide. The program targets rare and "undruggable" diseases that traditional pharmaceutical companies find commercially unattractive, using AI-orchestrated robotic automation to accelerate molecule discovery — including complex bispecific antibodies — while keeping human researchers in the loop.

The expansion signals a meaningful diversification of Anthropic's business beyond large language models ahead of its anticipated IPO, which has been discussed at valuations above $2 trillion. The company has backed the initiative with substance: a roughly $400 million acquisition of Coefficient Bio, the addition of Novartis CEO Vas Narasimhan to its board, and partnerships with Roche's Genentech, Bristol Myers Squibb, and Novo Nordisk. CEO Dario Amodei, whose father died before a cure emerged for his condition, is said to be personally invested in the program's success. Anthropic says it will not conduct clinical trials or compete directly with pharma, positioning itself instead as an AI-powered discovery engine for conditions the industry has historically ignored.

Pre-IPO derivatives markets are pricing Anthropic at $2.15–$2.36 trillion on the Hyperliquid platform, roughly 2.2x its last private valuation of $965 billion from the May 2025 Series H round led by Altimeter Capital, Dragoneer, Greenoaks, and Sequoia. The company has filed a confidential S-1 with Nasdaq selected as its listing venue, with Goldman Sachs, JPMorgan, and Morgan Stanley leading an offering expected to raise over $60 billion. Liquidity in the derivatives market remains thin — $6 million in 24-hour volume and $31 million in open interest — meaning the on-chain pricing reflects speculative appetite more than deep price discovery.

Fundamentals underlying the lofty pre-IPO multiple include an annualized revenue run rate of $65 billion as of July 2025, though the company reported approximately $42 billion in losses for 2025. Amazon has committed up to $33 billion in investment alongside an Anthropic pledge to spend over $100 billion on AWS over the next decade. The public S-1 filing, once released, will give prospective IPO investors their first detailed look at unit economics and the path to profitability behind a valuation that now rivals the largest public companies in the world.

SpaceX's June IPO offers a data-rich preview for prospective Anthropic investors. SpaceX priced at $135 per share but opened on Nasdaq around $150 and spiked as high as $168 on its debut day — meaning IPO allocations were profitable while most open-market buyers on day one were underwater. Retail access was uneven: Robinhood and SoFi opened IPO shares to all account holders regardless of balance, while Fidelity — which normally requires $500,000 in household assets — lowered its threshold to $2,000 specifically for the SpaceX offering, and not all brokers received allocations at all.

Post-debut volatility was also significant: SpaceX briefly crossed $200 within days of listing, then fell to a low of $108.27 by early August before averaging roughly $142 over the first three months. Yahoo Finance draws the parallel that Anthropic investors should anticipate comparable pricing gaps between the IPO price and first-day trading levels, verify in advance whether their broker will receive an allocation, and brace for sharp swings in the weeks following the listing.

SpaceX's post-IPO insider lockup structure — which raised over $85 billion including underwriters' overallotment and features nine scheduled lockup expiration periods running through end of 2026 — could constrain demand for Anthropic's own listing, according to a Motley Fool analysis published September 15. The argument: as SpaceX insiders sell shares in tranches, capital that might otherwise flow into Anthropic's IPO gets absorbed, leaving less dry powder for a second mega-offering in a compressed window. Anthropic is reportedly eyeing a September or October 2026 debut and is weighing lockup periods longer than the standard 180 days.

Beyond capital competition, the piece flags broader headwinds including what it calls "popular backlash against AI," which could further narrow the buyer pool for Anthropic's offering. The combination of staggered SpaceX supply hitting the market and muted retail enthusiasm for AI names creates a more challenging setup than Anthropic might face in a market without those concurrent pressures.

Anthropic CEO Dario Amodei published a 3,800-word essay calling on the AI industry to deliberately slow the pace of capabilities development, arguing that "risk prevention has time to keep up." His central message — "We must slow the pace at which we improve the capabilities of A.I. models" — focused on two systemic risks: inadequate safety and control mechanisms, and dangerous concentration of AI power among a small number of actors. Amodei proposed independent external reviewers, coordinated industry safety standards, and international cooperation as the mechanisms for managing AI development more prudently, stopping short of calling for an immediate halt to training or cuts in capital expenditure.

The essay triggered a broad selloff in AI-exposed equities, with semiconductor names including Marvell, SK Hynix, CoreWeave, AMD, and Micron falling 5–7%, and Nvidia and Broadcom declining roughly 3%. CoreWeave drew particular analyst attention given its heavy exposure to model-training infrastructure. OpenAI's Sam Altman publicly aligned with Amodei's framing, signaling that concerns about governance and pace are now shared at the top of both leading frontier labs — a shift that could carry meaningful implications for how regulators and investors assess the sector's trajectory.

Nvidia is reportedly in discussions to commit up to $10 billion as an anchor investor in Anthropic's upcoming IPO, which could value the AI company at as much as $2.3 trillion — potentially the largest listing in market history. The deal is said to be targeted to price before the U.S. midterm elections in November 2026, with Anthropic seeking to raise as much as $100 billion in total. Nvidia CFO Colette Kress noted the company has "invested nearly $50 billion in the Frontier AI Labs," describing it as "a small fraction of our expected free cash flow."

The investment would deepen an already significant commercial relationship: Anthropic's revenue run rate climbed above $65 billion by the end of July 2026, up from roughly $9 billion at the end of 2025, with the company projecting $190–200 billion in revenue by 2028. Anthropic is also adopting 1 gigawatt of compute capacity across Nvidia's Grace Blackwell and Vera Rubin systems, making it one of the chipmaker's largest customers and giving Nvidia a strategic incentive to anchor the offering.

Anthropic has launched a formal request for information from major wealth managers, asking firms to submit proposals covering fee structures, service offerings, and operational capabilities as it assembles a recommended list of financial advisers for employees ahead of an anticipated IPO. Goldman Sachs, Bank of America, JPMorgan Chase, Wells Fargo, Bank of New York Mellon, Citigroup, Morgan Stanley, and various boutique firms are among those competing for the mandate.

The process mirrors a similar effort by SpaceX prior to its listing, when more than 1,000 current and former employees collectively negotiated discounted rates and specialized tax-planning services. One industry observer described the Anthropic opportunity as "equivalent to a lottery ticket" for participating wealth managers, given the volume of new millionaires the IPO is expected to produce among staff who hold equity grants from the past two years.